NCT05446935 (CHOICE) is a NA clinical trial of HITOC in Thymic Epithelial Tumor, sponsored by Shanghai Zhongshan Hospital.

Who is sponsoring NCT05446935?

NCT05446935 is sponsored by Shanghai Zhongshan Hospital.

What drugs are being tested in NCT05446935?

Interventions in NCT05446935: HITOC.

What condition does NCT05446935 study?

NCT05446935 studies Thymic Epithelial Tumor.

Is NCT05446935 still recruiting?

NCT05446935 is currently status unknown. Last updated 19 September 2022.

Last reviewed 2022-09-19 · How we verify

NCT05446935: CHOICE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Intrathoracic Chemotherapy for TETs With Pleural Spread or Recurrence

Status unknown NA Last updated 19 September 2022

What this trial tests

NA trial testing HITOC in Thymic Epithelial Tumor in 37 participants. Status unknown.

Timeline

1 October 2022

Primary endpoint
30 November 2024

30 November 2025

Quick facts

Lead sponsor	Shanghai Zhongshan Hospital
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	37
Start date	1 October 2022
Primary completion	30 November 2024
Estimated completion	30 November 2025
Sites	1 location across China

Drugs / interventions tested

HITOC

Conditions studied

Thymic Epithelial Tumor — all drugs for Thymic Epithelial Tumor →

Sponsor

Shanghai Zhongshan Hospital

Who can join

Adults 16 to 80, any sex, with Thymic Epithelial Tumor. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Hyperthermic intrathoracic chemotherapy (HITOC) offers an additional treatment option for malignant pleural tumors after surgical cytoreduction. Especially it is used to further improve local tumor control in thymic malignancies with pleural spread, who underwent multimodality therapy including surgical resection. A phase II clinical study was conducted to explore the efficacy and safety of surgery followed by HITOC (POD1: DOX, POD2: cisplatin) for thymic epithelial tumors with pleural spread or recurrence.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Cytoreductive surgery combined with hyperthermic intrathoracic chemotherapy for the treatment of thymic epithelial malignancies with pleural spread or recurrence (CHOICE): a study protocol for a prospective, open, single-arm study.
Yang X, Wang S, Jiang J, Lin M, et al · · 2024 · cited 5× · PMID 38410567 · DOI 10.21037/jtd-23-759
Cytoreductive surgery and hyperthermic intrathoracic chemotherapy in thymic epithelial tumors with pleural spread or recurrence: a prospective, single-arm, phase II study.
Wang S, Yang X, Jiang J, Liang F, et al · · 2025 · cited 1× · PMID 40467556 · DOI 10.1038/s41467-025-60386-0

Verify or expand the search:

Other recruiting trials for Thymic Epithelial Tumor

Currently open trials in the same condition.

NCT06311955 — Clinical Study of Postoperative Carbon Ion Radiotherapy for Thymus Tumor With Residual Tumor · Phase 2 · recruiting
NCT06692062 — Hypofractionated Radiotherapy for Thymic Epithelial Tumors · NA · recruiting
NCT06301945 — Artificial Intelligence Prediction Tool in Thymic Epithelial Tumors · recruiting
NCT05104736 — PT-112 in Subjects With Thymoma and Thymic Carcinoma · Phase 2 · recruiting
NCT04417660 — Bintrafusp Alfa (M7824) in Subjects With Thymoma and Thymic Carcinoma · Phase 2 · active not recruiting

Other Shanghai Zhongshan Hospital trials

Trials by the same sponsor.

NCT07353476 — Radiotherapy Plus Anti-PD-1 Versus Anti-PD-1 Alone in ypTanyN⁺M0 NSCLC · Phase 2 · not yet recruiting
NCT07508956 — Feasibility of Circulating Tumor DNA Based Minimal Residual Disease-Guided Adjuvant Therapy in Locally Advanced Gastric · Phase 3 · not yet recruiting
NCT07535632 — SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cance · Phase 2 · not yet recruiting
NCT07531368 — BBAP With CS Mapping Guidance · NA · not yet recruiting
NCT07501104 — Neoadjuvant Pucotenlimab Combined With Lenvatinib and Temozolomide in Resectable Stage IIB/III Acral Melanoma · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05446935 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai Zhongshan Hospital
Last refreshed: 19 September 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05446935.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing